Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Portfolio Pulse from
Jaguar Health has extended its collaboration with Streeterville to develop NP-300 for cholera treatment and pursue a Tropical Disease Priority Review Voucher (TDPRV) from the FDA. With fewer PRVs available, the value of TDPRVs may increase, boosting interest in tropical diseases.
February 18, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health extends its collaboration to develop NP-300 for cholera and aims for a TDPRV from the FDA. The potential increase in TDPRV value could attract more investment in tropical diseases.
The extension of the collaboration and the pursuit of a TDPRV could lead to increased interest and investment in Jaguar Health, especially given the potential rise in TDPRV value due to fewer available PRVs. This development is significant for Jaguar Health's strategic positioning in the pharmaceutical market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90